JP2019529560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529560A5 JP2019529560A5 JP2019537047A JP2019537047A JP2019529560A5 JP 2019529560 A5 JP2019529560 A5 JP 2019529560A5 JP 2019537047 A JP2019537047 A JP 2019537047A JP 2019537047 A JP2019537047 A JP 2019537047A JP 2019529560 A5 JP2019529560 A5 JP 2019529560A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- patient
- csa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 23
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 23
- 239000003112 inhibitor Substances 0.000 claims 23
- 229930105110 Cyclosporin A Natural products 0.000 claims 16
- 108010036949 Cyclosporine Proteins 0.000 claims 16
- 229960001265 ciclosporin Drugs 0.000 claims 16
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 238000002560 therapeutic procedure Methods 0.000 claims 9
- 206010012438 Dermatitis atopic Diseases 0.000 claims 7
- 201000008937 atopic dermatitis Diseases 0.000 claims 7
- 229940125379 topical corticosteroid Drugs 0.000 claims 7
- 230000009885 systemic effect Effects 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 229960003444 immunosuppressant agent Drugs 0.000 claims 5
- 239000003018 immunosuppressive agent Substances 0.000 claims 5
- 230000001861 immunosuppressant effect Effects 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 3
- 229960001334 corticosteroids Drugs 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000011156 evaluation Methods 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003974 emollient agent Substances 0.000 claims 2
- 238000002483 medication Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000001126 phototherapy Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 208000035533 House dust allergy Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229940046731 calcineurin inhibitors Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000037851 severe atopic dermatitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 238000009121 systemic therapy Methods 0.000 claims 1
- 231100000402 unacceptable toxicity Toxicity 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022128592A JP2022160685A (ja) | 2016-09-22 | 2022-08-12 | Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
| JP2024153668A JP2024174962A (ja) | 2016-09-22 | 2024-09-06 | Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662397988P | 2016-09-22 | 2016-09-22 | |
| US62/397,988 | 2016-09-22 | ||
| US201762442083P | 2017-01-04 | 2017-01-04 | |
| US62/442,083 | 2017-01-04 | ||
| US201762443819P | 2017-01-09 | 2017-01-09 | |
| US62/443,819 | 2017-01-09 | ||
| US201762445774P | 2017-01-13 | 2017-01-13 | |
| US62/445,774 | 2017-01-13 | ||
| US201762519896P | 2017-06-15 | 2017-06-15 | |
| US62/519,896 | 2017-06-15 | ||
| EP17306081.5 | 2017-08-18 | ||
| EP17306081 | 2017-08-18 | ||
| PCT/US2017/052772 WO2018057776A1 (en) | 2016-09-22 | 2017-09-21 | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022128592A Division JP2022160685A (ja) | 2016-09-22 | 2022-08-12 | Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529560A JP2019529560A (ja) | 2019-10-17 |
| JP2019529560A5 true JP2019529560A5 (enExample) | 2020-10-22 |
| JP7164530B2 JP7164530B2 (ja) | 2022-11-01 |
Family
ID=59974890
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537047A Active JP7164530B2 (ja) | 2016-09-22 | 2017-09-21 | Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
| JP2022128592A Pending JP2022160685A (ja) | 2016-09-22 | 2022-08-12 | Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
| JP2024153668A Pending JP2024174962A (ja) | 2016-09-22 | 2024-09-06 | Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022128592A Pending JP2022160685A (ja) | 2016-09-22 | 2022-08-12 | Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
| JP2024153668A Pending JP2024174962A (ja) | 2016-09-22 | 2024-09-06 | Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220110999A1 (enExample) |
| EP (2) | EP4345110A3 (enExample) |
| JP (3) | JP7164530B2 (enExample) |
| KR (3) | KR20240146104A (enExample) |
| CN (2) | CN109963577B (enExample) |
| AU (2) | AU2017332732B2 (enExample) |
| CA (1) | CA3037499A1 (enExample) |
| ES (1) | ES2974376T3 (enExample) |
| HU (1) | HUE066662T2 (enExample) |
| IL (2) | IL265516B2 (enExample) |
| MX (3) | MX2019003235A (enExample) |
| PL (1) | PL3515465T3 (enExample) |
| RU (1) | RU2759630C2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
| RU2704999C2 (ru) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Способ лечения кожной инфекции путем введения антагониста il-4r |
| EP4442323A3 (en) | 2016-09-01 | 2025-01-01 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| CN111518211B (zh) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
| MX2021011141A (es) | 2019-03-21 | 2022-01-19 | Regeneron Pharma | Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia. |
| AU2020326713A1 (en) | 2019-08-05 | 2022-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| EP4010001A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| WO2002055101A2 (en) * | 2000-12-21 | 2002-07-18 | Inhale Therapeutic Syst | Storage stable powder compositions of interleukin-4 receptor |
| WO2005047331A2 (en) | 2003-11-07 | 2005-05-26 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| WO2008054606A2 (en) | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| KR101867279B1 (ko) | 2010-10-06 | 2018-06-15 | 리제너론 파아마슈티컬스, 인크. | 항―인터류킨―4 수용체(il-4r) 항체를 함유하는 안정화된 제형 |
| SI2892927T1 (sl) | 2012-09-07 | 2018-10-30 | Regeneron Pharmaceuticals,Inc | Metode zdravljenja atopijskega dermatitisa z dajanjem antagonista Il-4R |
| TWI682781B (zh) * | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| MA46269B1 (fr) | 2017-08-18 | 2024-05-31 | Regeneron Pharma | Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r |
-
2017
- 2017-09-21 AU AU2017332732A patent/AU2017332732B2/en active Active
- 2017-09-21 IL IL265516A patent/IL265516B2/en unknown
- 2017-09-21 CN CN201780071612.1A patent/CN109963577B/zh active Active
- 2017-09-21 PL PL17777145.8T patent/PL3515465T3/pl unknown
- 2017-09-21 CN CN202410243081.1A patent/CN118203659A/zh active Pending
- 2017-09-21 KR KR1020247032347A patent/KR20240146104A/ko active Pending
- 2017-09-21 KR KR1020227045686A patent/KR20230006049A/ko not_active Ceased
- 2017-09-21 ES ES17777145T patent/ES2974376T3/es active Active
- 2017-09-21 EP EP23216251.1A patent/EP4345110A3/en active Pending
- 2017-09-21 IL IL310371A patent/IL310371A/en unknown
- 2017-09-21 CA CA3037499A patent/CA3037499A1/en active Pending
- 2017-09-21 HU HUE17777145A patent/HUE066662T2/hu unknown
- 2017-09-21 EP EP17777145.8A patent/EP3515465B1/en active Active
- 2017-09-21 MX MX2019003235A patent/MX2019003235A/es unknown
- 2017-09-21 KR KR1020197011455A patent/KR20190053250A/ko not_active Ceased
- 2017-09-21 JP JP2019537047A patent/JP7164530B2/ja active Active
- 2017-09-21 RU RU2019111921A patent/RU2759630C2/ru active
-
2019
- 2019-03-21 MX MX2023014187A patent/MX2023014187A/es unknown
- 2019-03-21 MX MX2024011262A patent/MX2024011262A/es unknown
-
2021
- 2021-09-22 US US17/482,273 patent/US20220110999A1/en active Pending
-
2022
- 2022-08-12 JP JP2022128592A patent/JP2022160685A/ja active Pending
-
2024
- 2024-06-11 AU AU2024203951A patent/AU2024203951A1/en active Pending
- 2024-09-06 JP JP2024153668A patent/JP2024174962A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529560A5 (enExample) | ||
| CN106062000B (zh) | 通过施用il-4r拮抗剂治疗皮肤感染的方法 | |
| RU2019111921A (ru) | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r | |
| JP2022160685A5 (enExample) | ||
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| RU2019103943A (ru) | Применение антагонистов il-13 для лечения атопического дерматита | |
| JP2017507139A5 (enExample) | ||
| JP2016523863A5 (enExample) | ||
| KR20210010518A (ko) | Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법 | |
| JP2017512193A5 (enExample) | ||
| EP3487881B1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| JP2017511316A5 (enExample) | ||
| Choy et al. | Mepolizumab (Nucala) for severe eosinophilic asthma | |
| WO2023215769A1 (en) | Il-13 antibodies for the treatment of atopic dermatitis | |
| JPWO2021026205A5 (enExample) | ||
| JPWO2019222055A5 (enExample) | ||
| Rommer et al. | Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions | |
| JPWO2021195530A5 (enExample) | ||
| JP2019535716A5 (enExample) | ||
| TW202045537A (zh) | 化膿性汗腺炎的治療 | |
| HRP20191709T1 (hr) | Postupci liječenja nosne polipoze davanjem antagonista il-4r | |
| EP4126943A1 (en) | Methods for treating atopic dermatitis and related disorders | |
| RU2020140639A (ru) | Способы лечения атопического дерматита посредством введения ингибитора ил-4r | |
| JPWO2023028468A5 (enExample) | ||
| RU2024129648A (ru) | Способы лечения атопического дерматита посредством введения антагониста il-4r |